FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080318130> ?p ?o ?g. }

• W2080318130 endingPage "203S" @default.
• W2080318130 startingPage "188S" @default.
• W2080318130 abstract "This article about unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. UFH is a heterogeneous mixture of glycosaminoglycans that bind to antithrombin via a pentasaccharide, catalyzing the inactivation of thrombin and other clotting factors. UFH also binds endothelial cells, platelet factor 4, and platelets, leading to rather unpredictable pharmacokinetic and pharmacodynamic properties. Variability in activated partial thromboplastin time (aPTT) reagents necessitates site-specific validation of the aPTT therapeutic range in order to properly monitor UFH therapy. Lack of validation has been an oversight in many clinical trials comparing UFH to LMWH. In patients with apparent heparin resistance, anti-factor Xa monitoring may be superior to measurement of aPTT. LMWHs lack the nonspecific binding affinities of UFH, and, as a result, LMWH preparations have more predictable pharmacokinetic and pharmacodynamic properties. LMWHs have replaced UFH for most clinical indications for the following reasons: (1) these properties allow LMWHs to be administered subcutaneously, once daily without laboratory monitoring; and (2) the evidence from clinical trials that LMWH is as least as effective as and is safer than UFH. Several clinical issues regarding the use of LMWHs remain unanswered. These relate to the need for monitoring with an anti-factor Xa assay in patients with severe obesity or renal insufficiency. The therapeutic range for anti-factor Xa activity depends on the dosing interval. Anti-factor Xa monitoring is prudent when administering weight-based doses of LMWH to patients who weigh > 150 kg. It has been determined that UFH infusion is preferable to LMWH injection in patients with creatinine clearance of < 25 mL/min, until further data on therapeutic dosing of LMWHs in renal failure have been published. However, when administered in low doses prophylactically, LMWH is safe for therapy in patients with renal failure. Protamine may help to reverse bleeding related to LWMH, although anti-factor Xa activity is not fully normalized by protamine. The synthetic pentasaccharide fondaparinux is a promising new antithrombotic agent for the prevention and treatment of venous thromboembolism. This article about unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. UFH is a heterogeneous mixture of glycosaminoglycans that bind to antithrombin via a pentasaccharide, catalyzing the inactivation of thrombin and other clotting factors. UFH also binds endothelial cells, platelet factor 4, and platelets, leading to rather unpredictable pharmacokinetic and pharmacodynamic properties. Variability in activated partial thromboplastin time (aPTT) reagents necessitates site-specific validation of the aPTT therapeutic range in order to properly monitor UFH therapy. Lack of validation has been an oversight in many clinical trials comparing UFH to LMWH. In patients with apparent heparin resistance, anti-factor Xa monitoring may be superior to measurement of aPTT. LMWHs lack the nonspecific binding affinities of UFH, and, as a result, LMWH preparations have more predictable pharmacokinetic and pharmacodynamic properties. LMWHs have replaced UFH for most clinical indications for the following reasons: (1) these properties allow LMWHs to be administered subcutaneously, once daily without laboratory monitoring; and (2) the evidence from clinical trials that LMWH is as least as effective as and is safer than UFH. Several clinical issues regarding the use of LMWHs remain unanswered. These relate to the need for monitoring with an anti-factor Xa assay in patients with severe obesity or renal insufficiency. The therapeutic range for anti-factor Xa activity depends on the dosing interval. Anti-factor Xa monitoring is prudent when administering weight-based doses of LMWH to patients who weigh > 150 kg. It has been determined that UFH infusion is preferable to LMWH injection in patients with creatinine clearance of < 25 mL/min, until further data on therapeutic dosing of LMWHs in renal failure have been published. However, when administered in low doses prophylactically, LMWH is safe for therapy in patients with renal failure. Protamine may help to reverse bleeding related to LWMH, although anti-factor Xa activity is not fully normalized by protamine. The synthetic pentasaccharide fondaparinux is a promising new antithrombotic agent for the prevention and treatment of venous thromboembolism." @default.
• W2080318130 created "2016-06-24" @default.
• W2080318130 creator A5000914852 @default.
• W2080318130 creator A5088502644 @default.
• W2080318130 date "2004-09-01" @default.
• W2080318130 modified "2023-10-18" @default.
• W2080318130 title "Heparin and Low-Molecular-Weight Heparin" @default.
• W2080318130 cites W114021389 @default.
• W2080318130 cites W1220174878 @default.
• W2080318130 cites W142321255 @default.
• W2080318130 cites W143004001 @default.
• W2080318130 cites W1493150376 @default.
• W2080318130 cites W1493306598 @default.
• W2080318130 cites W1514571277 @default.
• W2080318130 cites W1517218704 @default.
• W2080318130 cites W1524312435 @default.
• W2080318130 cites W1524830639 @default.
• W2080318130 cites W1527283637 @default.
• W2080318130 cites W1527418628 @default.
• W2080318130 cites W1531766605 @default.
• W2080318130 cites W1560970554 @default.
• W2080318130 cites W156816327 @default.
• W2080318130 cites W1585004555 @default.
• W2080318130 cites W1600823549 @default.
• W2080318130 cites W1604026341 @default.
• W2080318130 cites W161900742 @default.
• W2080318130 cites W162720999 @default.
• W2080318130 cites W1674009589 @default.
• W2080318130 cites W176762677 @default.
• W2080318130 cites W177245439 @default.
• W2080318130 cites W1786317249 @default.
• W2080318130 cites W1792897501 @default.
• W2080318130 cites W1798638067 @default.
• W2080318130 cites W1837500700 @default.
• W2080318130 cites W1855915925 @default.
• W2080318130 cites W1964506112 @default.
• W2080318130 cites W1968806547 @default.
• W2080318130 cites W1969170064 @default.
• W2080318130 cites W1970672170 @default.
• W2080318130 cites W1970680336 @default.
• W2080318130 cites W1972161933 @default.
• W2080318130 cites W1972706485 @default.
• W2080318130 cites W1972760043 @default.
• W2080318130 cites W1973261201 @default.
• W2080318130 cites W1974718993 @default.
• W2080318130 cites W1977452105 @default.
• W2080318130 cites W1977798903 @default.
• W2080318130 cites W1981028815 @default.
• W2080318130 cites W1983331402 @default.
• W2080318130 cites W1983585487 @default.
• W2080318130 cites W1985485198 @default.
• W2080318130 cites W1986948615 @default.
• W2080318130 cites W1987067574 @default.
• W2080318130 cites W1989080352 @default.
• W2080318130 cites W1990784862 @default.
• W2080318130 cites W1993350032 @default.
• W2080318130 cites W1995116261 @default.
• W2080318130 cites W1995844663 @default.
• W2080318130 cites W1999121204 @default.
• W2080318130 cites W1999450294 @default.
• W2080318130 cites W2000038591 @default.
• W2080318130 cites W2000130043 @default.
• W2080318130 cites W2002600260 @default.
• W2080318130 cites W2003915795 @default.
• W2080318130 cites W2004746423 @default.
• W2080318130 cites W2006868468 @default.
• W2080318130 cites W2008094121 @default.
• W2080318130 cites W2008254616 @default.
• W2080318130 cites W2008913995 @default.
• W2080318130 cites W2010280774 @default.
• W2080318130 cites W2012678334 @default.
• W2080318130 cites W2016822743 @default.
• W2080318130 cites W2018622691 @default.
• W2080318130 cites W20197546 @default.
• W2080318130 cites W2020538652 @default.
• W2080318130 cites W2021746499 @default.
• W2080318130 cites W2022068650 @default.
• W2080318130 cites W2023820419 @default.
• W2080318130 cites W2023886702 @default.
• W2080318130 cites W2028889338 @default.
• W2080318130 cites W2033724005 @default.
• W2080318130 cites W2035959805 @default.
• W2080318130 cites W2037980538 @default.
• W2080318130 cites W2037985170 @default.
• W2080318130 cites W2039017397 @default.
• W2080318130 cites W2039989814 @default.
• W2080318130 cites W2040042544 @default.
• W2080318130 cites W2040777539 @default.
• W2080318130 cites W2040919322 @default.
• W2080318130 cites W2041182123 @default.
• W2080318130 cites W2041536445 @default.
• W2080318130 cites W2041801596 @default.
• W2080318130 cites W2042254867 @default.
• W2080318130 cites W2043340874 @default.
• W2080318130 cites W2043903998 @default.
• W2080318130 cites W2044768415 @default.
• W2080318130 cites W2045716011 @default.
• W2080318130 cites W2046027264 @default.

• next